EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069

Recruiting N/A Interventional Study
Mild Cognitive Impairment (MCI) Subjective Cognitive Complaints (SCCs) Parkinson Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 85
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
60 (estimated)
Sponsor
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The increase in life expectancy in recent decades has led to a large number of people living into old age and an increased risk of developing Chronic Neurological Diseases (CNDs) such as neurodegenerative diseases. A higher cumulative risk of dementia has been largely demonstrated in Mild Cognitive Impairment (MCI) and Subjective Cognitive Complaints (SCCs) subjects and in Parkinson's Disease (PD)…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosis of PD (Hoehn \& Yahr\<3); MCI (with CDR scale≤0.5, MMSE ≥24), and SCC (Subjective Cognitive Complaints); * Montreal Cognitive Assessment (MoCA) corrected score ≥17.36 * Education ≥ 5 years * Age eligible for the study: 18≤age≤85 * Native Italian speakers * Absence of…
Contacts

Maria Cotelli, PhD

+390303501457

mcotelli@fatebenefratelli.eu

CONTACT

Rosa Manenti, PhD

+390303501457

rmanenti@fatebenefratelli.eu

CONTACT